Mablink presents at the digital 9th Antibody Industrial Symposium (June 22-25, 2021) Our Chief Scientific Officer, Dr Warren Viricel, is giving a presentation at the 9th virtual Antibody Industrial Symposium …
Dr. Warren Viricel, our company’s Chief Scientific Officer, is invited to present Mablink’s PSARlink™ drug-linker technology at the 12th annual PEGS Europe Virtual summit (Lisbon, PT) on Tuesday, November 10, …
Mablink’s Chief Scientific Officer Warren Viricel presents preclinical data of our drug-linker ADC platform based on the topoisomerase I inhibitor Exatecan vs. HER-2 ADC gold standard Enhertu® in a mouse …
Mablink will present preclinical data of our drug-linker ADC platform based on a topoisomerase I inhibitor vs. gold standard Enhertu in a mouse model of gastric cancer.
Mablink will take the opportunity to meet with pharmaceutical companies and investors during MEET2WIN, the European oncology partnering convention entirely dedicated to open innovation, collaborative research and technology transfer. Two vibrant days dedicated to oncology and innovation.
Mablink Bioscience will present the latest technological advances of its ADC platform for highly-loaded & highly hydrophilic ADCs
Mablink Bioscience is looking forward to the 10th edition of the World ADC congress in London, Europe’s longest standing and most comprehensive forum in the ADC field.
Discover Mablink’s ADC platform and meet our COO Valérie Attuil-Audenis and our CEO Jean-Guillaume Lafay at BioFIT Event on December 10 and 11 in Marseille
